X0306 4/A 2022-07-05 2022-07-07 0001401667 PUMA BIOTECHNOLOGY, INC. PBYI 0001758507 NOUGUES MAXIMO F C/O PUMA BIOTECHNOLOGY, INC. 10880 WILSHIRE BLVD., SUITE 2150 LOS ANGELES CA 90024 1 Chief Financial Officer Common Stock 2022-07-05 4 S 0 9328 2.6315 D 111738 D The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. On July 7, 2022, the Reporting Person filed a Form 4 which inadvertently reported that 5,835 shares of Common Stock were disposed in the transaction, following which a total of 64,625 shares of Common Stock were beneficially owned by the Reporting Person. In fact, as reported in this amendment, the Reporting Person disposed of 9,328 shares of Common Stock, following which the Reporting Person directly owned 111,738 shares of Common Stock. /s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues 2022-08-04